[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201270280A1 - Соединения пиримидина в качестве ингибиторов при лечении туберкулеза - Google Patents

Соединения пиримидина в качестве ингибиторов при лечении туберкулеза

Info

Publication number
EA201270280A1
EA201270280A1 EA201270280A EA201270280A EA201270280A1 EA 201270280 A1 EA201270280 A1 EA 201270280A1 EA 201270280 A EA201270280 A EA 201270280A EA 201270280 A EA201270280 A EA 201270280A EA 201270280 A1 EA201270280 A1 EA 201270280A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tuberculosis
inhibitors
treatment
pyrimidine compounds
compounds
Prior art date
Application number
EA201270280A
Other languages
English (en)
Inventor
Тяньшэн Ван
Брайан Ханцелька
Уте Мух
Гай Бемис
Хармон Дж. Дзуккола
Original Assignee
Вертекс Фармасьютикалз Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вертекс Фармасьютикалз Инкорпорейтед filed Critical Вертекс Фармасьютикалз Инкорпорейтед
Publication of EA201270280A1 publication Critical patent/EA201270280A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к соединениям II, применяемым в качестве ингибиторов при лечении туберкулеза. Изобретение также предлагает способ получения заявленных соединений.
EA201270280A 2009-08-14 2010-08-13 Соединения пиримидина в качестве ингибиторов при лечении туберкулеза EA201270280A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23406309P 2009-08-14 2009-08-14
PCT/US2010/002244 WO2011019405A1 (en) 2009-08-14 2010-08-13 Pyrimidine compounds as tuberculosis inhibitors

Publications (1)

Publication Number Publication Date
EA201270280A1 true EA201270280A1 (ru) 2013-01-30

Family

ID=42735783

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270280A EA201270280A1 (ru) 2009-08-14 2010-08-13 Соединения пиримидина в качестве ингибиторов при лечении туберкулеза

Country Status (8)

Country Link
US (2) US20110053916A1 (ru)
EP (1) EP2464641B1 (ru)
JP (1) JP2013501785A (ru)
KR (1) KR20120089648A (ru)
CN (1) CN102656164A (ru)
EA (1) EA201270280A1 (ru)
WO (1) WO2011019405A1 (ru)
ZA (1) ZA201200972B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367690B2 (en) 2009-03-24 2013-02-05 Vertex Pharmaceuticals Inc. Aminopyridine derivatives having aurora a selective inhibitory action
JP5708161B2 (ja) * 2011-04-04 2015-04-30 住友化学株式会社 含カルコゲン縮合多環式化合物の製造方法
CN102796807B (zh) * 2011-05-25 2014-04-30 中国医学科学院医药生物技术研究所 一种筛选PknB抑制剂的反应体系及其筛选方法
WO2013033862A1 (zh) * 2011-09-05 2013-03-14 浙江海正药业股份有限公司 具有蛋白激酶抑制活性的4-取代-(3-取代-1h-吡唑-5-氨基)-嘧啶衍生物及其用途
CN104672147A (zh) * 2015-02-17 2015-06-03 衢州学院 一种2,4-二羟基-5-嘧啶甲酸甲酯的制备方法
AU2016295165B2 (en) * 2015-07-17 2021-04-22 The Global Alliance For Tb Drug Development, Inc. Substituted phenyloxazolidinones for antimicrobial therapy
WO2019046163A1 (en) * 2017-08-28 2019-03-07 Zhihong Chen SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND ASSOCIATED THERAPEUTIC METHODS
CN108558858A (zh) * 2018-05-23 2018-09-21 成都师范学院 硝基呋喃类抗结核化合物
MA55322A (fr) * 2019-03-15 2022-01-19 Massachusetts Gen Hospital Nouveaux inhibiteurs à petites molécules de facteurs de transcription tead
JP7085697B2 (ja) 2019-11-01 2022-06-16 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法
WO2022107919A1 (ko) * 2020-11-19 2022-05-27 주식회사 보로노이 N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
WO2023163712A1 (en) * 2022-02-25 2023-08-31 Nalo Therapeutics Modulators of myc family proto-oncogene protein
TW202348225A (zh) * 2022-02-25 2023-12-16 美商納羅醫療公司 Myc家族原癌基因蛋白之調節劑
CN114751909B (zh) * 2022-03-17 2023-10-27 杭州福斯特药业有限公司 一种瑞博西尼中间体的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154747A0 (en) * 2000-09-15 2003-10-31 Vertex Pharma Pyrazole derivatives and pharmaceutical compositions containing the same
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
WO2005040159A1 (en) * 2003-10-17 2005-05-06 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
ATE519759T1 (de) * 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
US20080167297A1 (en) * 2005-04-05 2008-07-10 Astrazeneca Ab Pyrimidine Derivatives for Use as Anticancer Agents
GB0506886D0 (en) * 2005-04-05 2005-05-11 Astrazeneca Ab Chemical compounds
WO2007023382A2 (en) * 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds

Also Published As

Publication number Publication date
ZA201200972B (en) 2013-05-29
US20110053916A1 (en) 2011-03-03
JP2013501785A (ja) 2013-01-17
CN102656164A (zh) 2012-09-05
EP2464641A1 (en) 2012-06-20
EP2464641B1 (en) 2014-06-25
KR20120089648A (ko) 2012-08-13
US20140249137A1 (en) 2014-09-04
US9422271B2 (en) 2016-08-23
WO2011019405A1 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
EA201171367A1 (ru) Винилиндазолильные соединения
TN2011000673A1 (en) Bace inhibitors
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
JO3025B1 (ar) الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
MX2014010551A (es) N-ciclilamidas como nematicidas.
EA201490886A1 (ru) Переработка биомассы
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201491303A1 (ru) Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps
MY159186A (en) Method for preparing small crystal ssz-32
MX2012007341A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
CL2012003491A1 (es) Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva.
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
GEP201706626B (en) Synthesis of (s)-nifuratel
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
TN2011000355A1 (en) Novel microbiocides
UA106886C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та проміжні сполуки магнію
GB201107985D0 (en) Process